Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

140.06
+0.87000.63%
Post-market: 141.000.9400+0.67%19:30 EDT
Volume:760.30K
Turnover:106.23M
Market Cap:9.06B
PE:135.98
High:141.71
Open:140.99
Low:138.37
Close:139.19
52wk High:160.81
52wk Low:62.24
Shares:64.71M
Float Shares:63.17M
Volume Ratio:0.97
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-2.0500
ROE:10.98%
ROA:4.55%
PB:10.77
PE(LYR):-68.32

Loading ...

Protagonist Therapeutics (PTGX) Could Be 25% Undervalued On Its Royalty Backed Story

Simply Wall St.
·
6 hours ago

Protagonist Therapeutics CFO Ali Asif Disposes of Common Shares Worth $8,314,337.28

Reuters
·
16 hours ago

The Peptide Boom That Isn't About Your Muscles - Heard on the Street

Dow Jones
·
Sep 25

Protagonist Therapeutics CEO Dinesh V. Patel Disposes of Common Shares Worth USD 18.25 Million

Reuters
·
Sep 11

Protagonist Therapeutics announces $300M share repurchase program

TIPRANKS
·
Sep 09

Protagonist Therapeutics Launches USD 300 Million Share Buyback Program

Reuters
·
Sep 09

Protagonist Therapeutics CEO Patel Joins Fireside Chats at Two Investment Bank Conferences

Reuters
·
Sep 02

Protagonist Therapeutics Price Target Raised to $180.00/Share from $153.00 by Barclays

Dow Jones
·
Sep 02

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), Teladoc (TDOC) and Protagonist Therapeutics (PTGX)

TIPRANKS
·
Sep 01

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)

TIPRANKS
·
Sep 01

Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says

MT Newswires Live
·
Sep 01

Citigroup Raises Protagonist Therapeutics Price Target to $182 From $175, Buy Rating Kept

MT Newswires Live
·
Sep 01

Protagonist Therapeutics price target raised to $170 from $165 at Citizens

TIPRANKS
·
Sep 01

Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says

MT Newswires Live
·
Aug 31

Protagonist Therapeutics is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 31

Protagonist Therapeutics (PTGX) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Aug 31

U.S. Research Roundup-Adobe, Braveheart Bio, CACI International

Reuters
·
Aug 31

Protagonist Therapeutics, Inc. : Jefferies Raises Target Price to $171 from $169

THOMSON REUTERS
·
Aug 31

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

TIPRANKS
·
Aug 31

Why Protagonist Therapeutics (PTGX) Is Down 6.5% After FDA Approval Triggers $275M Milestone Payment

Simply Wall St.
·
Aug 30